Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

MicroConstants In-Licenses China-Discovered Antibody for $16 Million

publication date: Jan 30, 2015
MicroConstants China in-licensed global rights to novel discovered-in-China AA98 antibodies from Beijing's Institute of Biophysics, Chinese Academy of Sciences. With anti-angiogenesis and anti-metastasis mechanisms, AA98 antibodies are possible treatments for various cancers, multiple sclerosis and age-related macular degeneration. The AA98 drug candidates covered in the agreement were developed in the lab of Prof. Xiyun Yan, Director of IBP's Key Laboratory of Protein and Peptide Drugs. MicroConstants agreed to a package of more than $16 million in upfront and development milestones plus royalties on sales. The deal includes an AA98-based diagnostic. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital